Everest Medicines (HKG: 1952) announced that it has entered into a strategic cooperation framework agreement with Hi‑Sen Pharmaceutical, establishing a framework for the supply, distribution, and related manufacturing and commercialization in China of six products: ceftriaxone sodium, somatostatin, urapidil, voglibose, azilsartan medoxomil, and candesartan cilexetil. The product list remains subject to updates pursuant to sub‑agreements.
Deal Overview
| Item | Detail |
|---|---|
| Parties | Everest Medicines (HKG: 1952) and Hi‑Sen Pharmaceutical |
| Announcement Date | 2 Nov 2026 |
| Agreement Type | Strategic cooperation framework agreement – supply, distribution, and related manufacturing & commercialization in China |
| Products Covered (Six) | Ceftriaxone sodium, somatostatin, urapidil, voglibose, azilsartan medoxomil, candesartan cilexetil |
| Product List Flexibility | Subject to updates pursuant to sub‑agreements |
| Fee Cap (2026–2028) | Maximum annual service fees payable by the Hi‑Sen Group of RMB 560 million (FY2026), RMB 616 million (FY2027), and RMB 677 million (FY2028) |
Product Portfolio Profile
- Ceftriaxone Sodium: A widely used third‑generation cephalosporin antibiotic for bacterial infections across hospital settings.
- Somatostatin: A peptide hormone therapy employed in acute gastrointestinal bleeding, pancreatic disorders, and endocrine tumor management.
- Urapidil: An antihypertensive agent used in the management of elevated blood pressure, including hospital acute care.
- Voglibose: An alpha‑glucosidase inhibitor for type 2 diabetes, targeting postprandial glucose control.
- Azilsartan Medoxomil: An angiotensin II receptor blocker (ARB) for hypertension with established cardiovascular use.
- Candesartan Cilexetil: A long‑acting ARB indicated for hypertension and heart failure management.
- Portfolio Logic: A diversified basket spanning anti‑infectives, cardiovascular, metabolic, and acute‑care categories – all high‑volume hospital and retail channel products in China.
Cooperation Models & Commercial Structure
- Commercialization Service Model: Everest Medicines will continue to provide commercialization services in China for designated products under existing commercialization service agreements, including local distribution and promotion services, nationwide marketing and promotion services, distributor selection and management services, sales forecasting services, hospital bidding services, and other commercial activities.
- Potential Cooperation Model: Subject to definitive transaction terms with relevant third parties, Everest Medicines may directly procure relevant products from applicable marketing authorization holders (MAHs) or other independent third parties – rather than from the Hi‑Sen Group – and would only need to pay a portion of the overall economic benefits to the Hi‑Sen Group.
- Annual Fee Ceilings: Maximum annual service fees payable by the Hi‑Sen Group to the Group for the three fiscal years ending 31 Dec 2026, 2027, and 2028 are capped at RMB 560 million, RMB 616 million, and RMB 677 million, respectively – implying built‑in year‑over‑year growth of 10% across the cap schedule.
Market Impact & Outlook
- Revenue Visibility: The three‑year fee caps totaling RMB 1.853 billion provide a clearly defined envelope for the commercialization partnership and signal management’s expectation of sustained, scaled collaboration.
- Asset‑Light Expansion: The potential cooperation model allows Everest Medicines to source products directly from MAHs, reducing dependence on Hi‑Sen supply while retaining a service‑fee revenue stream – enhancing margin flexibility.
- Commercial Infrastructure Leverage: The agreement monetizes Everest Medicines’ established nationwide distribution, promotion, and hospital bidding capabilities across six high‑volume generic and specialty hospital products.
- Framework Flexibility: With the product list open to updates via sub‑agreements, the partnership can expand into additional molecules as both parties identify commercial opportunities.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic cooperation between Everest Medicines and Hi‑Sen Pharmaceutical, including definitive sub‑agreements, third‑party procurement arrangements, product list updates, and expected service fees. Actual results may differ materially due to risks including negotiation of definitive terms with relevant third parties, regulatory and bidding dynamics in China’s pharmaceutical market, and commercialization execution.-Fineline Info & Tech
